02.06 Inflammatory Cytokines Outperform Endotheliopathy Markers as Early Predictors of Mortality in Trauma

E.R. Becker1, A.D. Price1, R.R. Shondel1, R.R. Schuster1, M.P. Smith1, T.A. Pritts1, M.D. Goodman1  1University Of Cincinnati, Department Of Surgery, Cincinnati, OH, USA

Introduction: Trauma induces cellular injury, coagulopathy, and a dysregulated physiologic response that result from endotheliopathy and the inflammatory response. This study aimed to compare early serum markers of endotheliopathy versus inflammatory cytokines to predict 30-day mortality in critically ill trauma patients.

Methods:  Serum samples were collected from 232 trauma patients upon admission to the ICU. Twelve endothelial markers were analyzed, including angiopoietin 1, E-selectin, P-selectin, syndecan-1, thrombomodulin, and vascular endothelial growth factors. Inflammatory cytokines analyzed included eotaxin, IL-1ra, IL-6, IL-8, IL-10, IP-10, and MCP-1. The primary outcome was 30-day mortality with subgroup analyses based on transfusion status at 4 hours, defined as massive (>4u pRBC+WB), sub massive (1-4units pRBC+WB), and no transfusion. 

Results: Subjects were 67% White, 67% male, with a median age of 58 years [34, 75]. Injuries were 88% blunt with a median injury severity score of 21 [14, 30] and a 7.3% mortality rate. By transfusion status, 19 (8%) patients required massive transfusion with 16% mortality, 40 (17%) required submassive transfusion with 13% mortality, and 173 (75%) did not require transfusion with 5% mortality. No endothelial marker was associated with mortality, even for transfusion subgroups. In contrast, 5 of the 7 inflammatory cytokines were associated with 30-day mortality (p<0.05) (Table). Inflammatory markers remained associated with mortality in the no transfusion cohort for eotaxin (p=0.04), IL-6 (p=0.005), and IL-8 (p=0.02), and the submassive transfusion cohort for IL-6 (p=0.045), IL-8 (p=0.04), and IP-10 (p=0.02). 

Conclusion: Post-injury inflammatory markers collected at the time of ICU admission offer potential 30-day mortality predictive value even in patients who do not undergo massive transfusion. In contrast, early markers of endotheliopathy may not predict mortality.